All Posts

Our CEO, Dr. Ana Montalban-Arques, spoke with Founded  about Adularia’s journey and our new approach in cancer therapy. The article...

We are pleased to announce that Adularia has been selected to present at the Biotech Europe Forum 2025 , taking place on October 8–9  in...

We are excited to announce that Adularia has been selected to present at the prestigious European Conference on Computational &...

This year, we will take part in LSX World Congress in London from the 28th to the 30th of April. This leading event brings together life...

We’re excited to participate in RESI Europe 2025 in Barcelona on 1st of April and virtually on the 2nd and 3rd of April. This event...

Highlights Serum transfer from CC4-treated mice reduces tumors and enhances CD8+ T cell activity 3OH Dodeca’s anti-tumor effect requires...

Abstract Colorectal cancer (CRC) is one of the most frequently diagnosed cancers and leading cause of cancer-related deaths worldwide. In...

Abstract A recent study by Montalban-Arques et al. 1  in Cell Host & Microbe shows that augmenting the function of the gut microbiota...

Highlights Clostridiales  bacteria are associated with low tumor burden in colon cancer models Selected Clostridiales  bacteria are...

We are excited to announce that Recolony is now Adularia . This change reflects an important shift in our company’s strategic direction...

We are beyond excited to share that Recolony has won the Top 100 Swiss Startups Public Voting 2024 in the Biotech category ! This award...

We’re Proud to Be Named One of the Top 100 Swiss Startups in 2024! Being included in this prestigious list is a testament to the hard...

The voting process will be opened until July 21 2024. You still have time to cast your vote using your LinkedIn account. You can vote for...

In a fascinating episode of the X-Health.show podcast, Ana Montalban-Arques, CEO of Recolony, discusses the potential of gut microbiota...

Ana Montalban-Arques, was recently featured on the Swisspreneur podcast, where she discussed our bacteria-based cancer therapy and shared...

Recolony ranks 10th in this annual ranking created by 100 leading investors and industry experts of the Swiss Startup scene.

Recolony enters the prestigious Top100 Swiss Startups ranking as newcomer in its first year of existence. The TOP 100 Swiss Startup Award...

Philipp Busenhart, CBO of Recolony, presents our company in this interview with the Handelzeitung

Recolony wins the Stage III of Venture Kick. Recolony will invest the CHF 150,000 awarded by Venture Kick to advance our small molecule...

The InnoBooster program from Gebert Rüf Stiftung aims at speeding up innovative, science-based deep tech businesses which have already...